

Resource Summary Report

Generated by PRECISE-TBI on Sep 1, 2026

RelB (D7D7W) Rabbit mAb

RRID:AB_2797727

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 10544, RRID:AB_2797727

Antibody Information

URL: http://antibodyregistry.org/AB_2797727

Proper Citation: Cell Signaling Technology Cat# 10544, RRID:AB_2797727

Target Antigen: RELB

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, F, ChIP

Antibody Name: RelB (D7D7W) Rabbit mAb

Description: This monoclonal targets RELB

Target Organism: h, m, r

Clone ID: Clone D7D7W

Antibody ID: AB_2797727

Vendor: Cell Signaling Technology

Catalog Number: 10544

Record Creation Time: 20250819T230225+0000

Record Last Update: 20250820T040624+0000

Ratings and Alerts

No rating or validation information has been found for RelB (D7D7W) Rabbit mAb.

No alerts have been found for RelB (D7D7W) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Valerio RR, et al. (2026) Innate Immune Tolerance Regulates Microglia Response to A β Oligomers. Journal of neurochemistry, 170(1), e70341.

Aggrey-Fynn JE, et al. (2026) Epigenetic context defines the transcriptional activity of canonical and noncanonical NF- κ B signaling in pancreatic cancer. Cell death discovery, 12(1).

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. Cell reports, 45(7), 117650.

Wu L, et al. (2025) Transcription elongation factor ELOF1 is required for efficient somatic hypermutation and class switch recombination. Molecular cell, 85(7), 1296.

Tang D, et al. (2025) Augment proteasome inhibitor efficacy activates CD8⁺ T cell-mediated antitumor immunity in breast cancer. Cell reports. Medicine, 6(7), 102211.

Ghosh A, et al. (2025) Potentiation of noncanonical NF- κ B signaling and marginal zone B cell expansion by CARD11-mediated regulation of p100 processing. Cell reports, 44(12), 116616.

Shen J, et al. (2024) Deubiquitylating Enzyme OTUB1 Facilitates Neuronal Survival After Intracerebral Hemorrhage Via Inhibiting NF- κ B-triggered Apoptotic Cascades. Molecular neurobiology, 61(3), 1726.

Liu M, et al. (2024) The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer cell, 42(5), 885.

Lan Y, et al. (2023) IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2. iScience, 26(8), 107377.

Xie J, et al. (2023) The miR-17-92 miRNAs promote plasma cell differentiation by suppressing SOCS3-mediated NIK degradation. Cell reports, 42(8), 112968.

Hermida-Prado F, et al. (2023) Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer research, 83(19), 3284.

Jahid S, et al. (2022) Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. Cell reports, 39(1), 110641.

Tong Y, et al. (2020) The RNFT2/IL-3R α axis regulates IL-3 signaling and innate immunity. JCI insight, 5(3).

Tan Y, et al. (2020) A marine fungus-derived nitrobenzoyl sesquiterpenoid suppresses receptor activator of NF- κ B ligand-induced osteoclastogenesis and inflammatory bone destruction. British journal of pharmacology, 177(18), 4242.